Download raw/aaer/2017/AAER-3846.txt from codewithdark/SEC-RPT-Panel: direct link, hf CLI and curl.
- Browser
- Download file 36 kB
-
https://huggingface.co/datasets/codewithdark/SEC-RPT-Panel/resolve/main/raw/aaer/2017/AAER-3846.txt
- Command line
-
hf download hf://datasets/codewithdark/SEC-RPT-Panel/raw/aaer/2017/AAER-3846.txt
-
curl -L -o AAER-3846.txt https://huggingface.co/datasets/codewithdark/SEC-RPT-Panel/resolve/main/raw/aaer/2017/AAER-3846.txt
36 kB
| UNITED STATES OF AMERICA | |
| Before the | |
| SECURITIES AND EXCHANGE COMMISSION | |
| SECURITIES ACT OF 1933 | |
| Release No. 10282 / January 18, 2017 | |
| SECURITIES EXCHANGE ACT OF 1934 | |
| Release No. 79817 / January 18, 2017 | |
| ACCOUNTING AND AUDITING ENFORCEMENT | |
| Release No. 3846 / January 18, 2017 | |
| ADMINISTRATIVE PROCEEDING | |
| File No. 3-17792 | |
| In the Matter of | |
| JEFFREY HAMMEL, CPA | |
| Respondent. | |
| ORDER INSTITUTING PUBLIC | |
| ADMINISTRATIVE AND CEASE-AND- | |
| DESIST PROCEEDINGS PURSUANT TO | |
| SECTION 8A OF THE SECURITIES ACT OF | |
| 1933, SECTIONS 4C AND 21C OF THE | |
| SECURITIES EXCHANGE ACT OF 1934, | |
| AND RULE 102(E) OF THE COMMISSION’S | |
| RULES OF PRACTICE, MAKING | |
| FINDINGS AND IMPOSING REMEDIAL | |
| SANCTIONS AND A CEASE-AND-DESIST | |
| ORDER | |
| I. | |
| The Securities and Exchange Commission (“Commission”) deems it appropriate that | |
| public administrative and cease-and-desist proceedings be, and hereby are, instituted pursuant to | |
| Section 8A of the Securities Act of 1933 (“Securities Act”), Sections 4C1 and 21C2 of the | |
| 1 Section 4C provides, in relevant part, that: | |
| The Commission may censure any person, or deny, temporarily or permanently, to any person the privilege | |
| of appearing or practicing before the Commission in any way, if that person is found . . . (1) not to possess | |
| the requisite qualifications to represent others . . . (2) to be lacking in character or integrity, or to have | |
| engaged in unethical or improper professional conduct; or (3) to have willfully violated, or willfully aided | |
| and abetted the violation of, any provision of the securities laws or the rules and regulations thereunder. | |
| 2 Rule 102(e)(1)(iii) provides, in pertinent part, that: | |
| 2 | |
| Securities Exchange Act of 1934 (“Exchange Act”), and Rule 102(e)(1)(iii) of the Commission’s | |
| Rules of Practice against Jeffrey Hammel, CPA (“Hammel” or “Respondent”). | |
| II. | |
| In anticipation of the institution of these proceedings, Respondent has submitted an Offer | |
| of Settlement (“Offer”), which the Commission has determined to accept. Solely for the purpose | |
| of these proceedings and any other proceedings brought by or on behalf of the Commission, or to | |
| which the Commission is a party, and without admitting or denying the findings herein, except as | |
| to the Commission’s jurisdiction over him and the subject matter of these proceedings, which are | |
| admitted, and except as provided in Section IV.G. herein, Respondent consents to the entry of | |
| this Order Instituting Public Administrative and Cease-and-Desist Proceedings Pursuant to | |
| Section 8A of the Securities Act, Sections 4C and 21C of the Securities Exchange Act of 1934, | |
| and Rule 102(e) of the Commission’s Rules of Practice, Making Findings and Imposing | |
| Remedial Sanctions and a Cease-and-Desist Order (“Order”), as set forth below. | |
| III. | |
| On the basis of this Order and Respondent’s Offer, the Commission finds | |
| 3 that: | |
| SUMMARY | |
| This matter concerns the conduct of Jeffrey Hammel (“Hammel”) in connection with a | |
| financial restatement that occurred at Orthofix International, N.V. (“Orthofix”). Hammel served | |
| as the Chief Financial Officer (“CFO”) of Orthofix’s largest segment, its Spine Segment | |
| (“Spine”). In that role, Hammel was responsible for the accounting and financial functions of | |
| Spine, including preparing its operating results (which were included in Orthofix’s public filings | |
| with the Commission). | |
| From early 2011 to late 2012, Hammel recorded revenue on several transactions that | |
| resulted in the company making material misstatements in its public filings. In particular, | |
| improper revenue was recorded on three transactions with one of Orthofix’s largest international | |
| distributors, including one transaction in which the company sold a product that could not be | |
| resold due to Orthofix’s delay in providing a required associated product and two transactions in | |
| which payment for the product was contingent on approval of the product by a regulatory body. | |
| This recording of revenue upon shipment of the products for these three transactions was | |
| The Commission may . . . deny, temporarily or permanently, the privilege of appearing or practicing before | |
| it . . . to any person who is found…to have willfully violated, or willfully aided and abetted the violation of | |
| any provision of the Federal securities laws or the rules and regulations thereunder. | |
| 3 The findings herein are made pursuant to Respondent’s Offer and are not binding on any other person or | |
| entity in this or any other proceeding. | |
| 3 | |
| improper because it did not meet the fixed or determinable or collectability criteria for revenue | |
| recognition. | |
| As part of his job responsibilities, Hammel annually signed management representation | |
| letters on behalf of Spine that were provided to Orthofix’s independent auditors. Prior to the | |
| fiscal year 2012 audit of the company’s financials, Hammel was aware of transactions with | |
| extended credit terms and/or oral agreements. Despite his awareness in this regard, Hammel | |
| signed a letter to the company’s independent auditors in connection with the company’s fiscal | |
| year 2012 audit representing that he was not aware of any transactions with extended credit | |
| terms and/or oral agreements that had not been disclosed to the company’s independent auditors. | |
| By engaging in the foregoing conduct, Hammel was a cause of Orthofix’s violations of | |
| Securities Act Sections 17(a)(2) and 17(a)(3) and the reporting, books and records, and internal | |
| controls provisions of the federal securities laws. Hammel also violated Exchange Act Rules | |
| 13b2-2(b) and 13b2-1. | |
| RESPONDENT | |
| Jeffrey Hammel, 50, served as the Chief Financial Officer of Orthofix’s then-largest | |
| segment, its Spine Segment, from July 2010 to approximately February 2013. Hammel resigned | |
| from Orthofix in February 2013 prior to the issuance of the FY 2012 financial statements by | |
| Orthofix. Hammel is a Certified Public Accountant in the state of Ohio and maintained an active | |
| license until the license lapsed in 2008. | |
| FACTS | |
| A. Orthofix’s Business and Hammel’s Responsibilities | |
| 1. Orthofix’s business was primarily divided into two Global Business Segments during the | |
| relevant period – Spine and Orthopedics. Spine was Orthofix’s largest segment and | |
| contributed two-thirds of the company’s overall revenues. | |
| 2. Spine had several operating divisions during the relevant period including Orthofix | |
| Spinal Implants (“OSI”), which was responsible for international sales of spinal implants | |
| and related instruments. | |
| 3. From approximately July 2010 to February 2013, Hammel served as the Chief Financial | |
| Officer of the Spine Segment. In that role, Hammel was responsible for the accounting | |
| and financial functions of Spine, including preparing its operating results (which were | |
| included in Orthofix’s public filings with the Commission). Moreover, Hammel annually | |
| signed management representation letters and certifications on behalf of Spine that were | |
| provided to Orthofix’s independent auditors. | |
| 4. Hammel reported directly to Spine’s President, a salesperson, during the relevant period. | |
| The Spine President was in charge of Spine’s sales and overall management and had | |
| 4 | |
| several sales persons who worked under him, including an individual who served as | |
| Spine’s Vice President of Global Sales and Development (“Spine Sales VP”). | |
| 5. While Hammel reported directly to the Spine President during the relevant period, he also | |
| had dotted line reporting responsibility to Orthofix’s Corporate CFO. The Corporate | |
| CFO was responsible for the preparation of Orthofix’s public filings, including its | |
| consolidated financial results. | |
| 6. Spine sold various products including spinal and cervical implants and related | |
| instruments. Spine sold the above products through two primary methods: (i) sales of its | |
| products to U.S. and international distributors who then sold the products to hospitals and | |
| physicians, and (ii) sales of its products directly to hospitals and physicians in the U.S. | |
| B. Revenue Recognition Practices | |
| 7. With limited exceptions, Orthofix recognized revenue during the relevant period based on | |
| the “sell-in” method, which provides for revenue recognition upon shipment of products | |
| to the distributor. | |
| 8. ASC 605-10-25-1 provides that revenue may be recognized only when it is both realized | |
| or realizable and earned. Consistent with the authoritative literature, Orthofix’s financial | |
| statements disclosed four criteria as its revenue recognition policy. | |
| 9. The four criteria are: (i) persuasive evidence of an arrangement exists; (ii) delivery has | |
| occurred or services have been rendered; (iii) the seller’s price to the buyer is fixed and | |
| determinable; and (iv) collectability is reasonably assured. | |
| C. Hammel Improperly Recorded Revenue on Transactions with Brazilian Distributor | |
| a. Implants without Instruments Transactions | |
| 10. OSI had several international distributors during the relevant period, but its largest | |
| distributor of product was located in Brazil (hereinafter “the Brazilian Distributor”). In | |
| fact, for eight of the nine quarters from Q1 2011 to Q1 2013, the Brazilian Distributor | |
| was the Company’s second largest customer on a revenue per quarter basis. | |
| 11. Entering 2011, Orthofix (and OSI) had a receivable of approximately $5 million from the | |
| Brazilian Distributor from prior sales. The Brazilian Distributor forecasted that it would | |
| purchase approximately $8.5 million of Orthofix implants and instruments in FY 2011. | |
| 12. Prior to this time, the Brazilian Distributor agreed to purchase implants along with | |
| instrument sets previously used in surgeries from Orthofix. Implants and instruments | |
| were interconnected because the implants could not be used in patients without related | |
| instrument sets. | |
| 5 | |
| 13. At this time, however, the Brazilian Distributor could no longer purchase previously used | |
| instrument sets because ANVISA (the Brazilian equivalent of the U.S. Food and Drug | |
| Administration) imposed new regulations prohibiting the importation of used instrument | |
| sets. | |
| 14. Orthofix (and OSI) did not have the new instrument sets (105 in total) available to be | |
| shipped along with the implants it shipped to the Brazilian Distributor. Rather than | |
| waiting until the new instrument sets were available, Orthofix – in FY 2011 – shipped | |
| approximately $5 million in implants to the Brazilian Distributor despite the fact that | |
| these implants could not be used in patients without the new instrument sets. | |
| 15. Orthofix recognized the approximately $5 million revenue upon shipment of the above | |
| implants. This recognition of revenue was improper as delivery of the interconnected | |
| product – the instruments – had not yet occurred. As such, payment timing and terms | |
| were contingent upon the instrument sets being made available and therefore, revenue | |
| recognition was inconsistent with Orthofix’s accounting policy because it did not meet | |
| the fixed or determinable criteria or the collectability criteria. | |
| 16. This improper recognition of revenue caused Orthofix’s financial statements to be | |
| materially misstated in its Forms 10-Q for the second and third quarters of FY 2011 and | |
| its year-end Form 10-K for FY 2011 and corresponding earnings releases. | |
| 17. As of the summer of 2012, virtually none of the 105 instrument sets had been shipped to | |
| the Brazilian Distributor. Thus, the Brazilian Distributor refused to pay for the implants | |
| because those implants that Orthofix had previously shipped to the Brazilian Distributor | |
| could not be used without the instrument sets. | |
| 18. Hammel became aware subsequent to the shipment of the implants that the corresponding | |
| 105 instrument sets had not been delivered, but did not take sufficient steps to evaluate | |
| the impact of the continued non-delivery of the instrument sets on the previously | |
| recognized revenue. | |
| 19. In fact, as of August 2012 all of the corresponding instrument sets had still not been | |
| delivered and – at that time – Hammel knew that (i) the Brazilian Distributor had been | |
| provided extended payment terms to pay for the implants and (ii) the Brazilian | |
| Distributor could not sell the implants because Orthofix was delayed in sending the | |
| corresponding instrument sets. | |
| b. Firebird Transaction | |
| 20. In late May 2012, the Spine President discussed a product launch plan with the Brazilian | |
| Distributor to purchase approximately $2.5 million of a new Orthofix product called | |
| Firebird. This product, however, had not yet been approved by ANVISA and, therefore, | |
| could not be shipped into Brazil until such approval was obtained. | |
| 6 | |
| 21. The Brazilian Distributor agreed to place the order on the following conditions: (i) one | |
| year to pay for the implants from the date of anticipated ANVISA approval; (ii) 210 days | |
| to pay on all subsequent product orders; and (iii) all corresponding instrument sets | |
| needed to be available once ANVISA approved the implants. No one knew when | |
| ANVISA would grant approval. | |
| 22. At this time, Spine had an unwritten policy that modifications to the terms in existing | |
| distributor agreements be approved by Hammel. The Spine Sales VP and Spine President | |
| agreed to the Firebird order terms without approval from Hammel. | |
| 23. Hammel learned of this transaction a few weeks after the product had been shipped to the | |
| warehouse but before the company filed its third quarter FY 2012 financial results. In | |
| particular – on July 24, 2012 – the Spine Sales VP forwarded Hammel an email | |
| describing the transaction along with a series of emails containing prior discussions | |
| between him and the Brazilian Distributor’s President. | |
| 24. Hammel replied to the Spine Sales VP – “[Spine Sales VP], can you please address how | |
| we ended up with a full year to pay for the June order. I have a hard time managing that | |
| with a lot of pressure to reduce our ballooning [Days Sales Outstanding].” The Spine | |
| Sales VP replied, “we accepted this due to the need for that size of an order.” | |
| 25. Despite the contingent nature of the sale and Hammel’s own concerns about how this | |
| transaction would impact the company’s Days Sales Outstanding, Hammel recognized | |
| over $2 million in revenue from this transaction immediately upon shipping the implants | |
| to the Brazilian Distributor’s warehouse located in the United States. | |
| 26. The recognition of revenue here was improper because the Brazilian Distributor’s | |
| obligation to pay, and the payment terms themselves, were contingent upon ANVISA | |
| approval and, therefore, revenue recognition was inconsistent with Orthofix’s accounting | |
| policy because it did not meet the fixed or determinable criteria or the collectability | |
| criteria. | |
| c. Fall 2012 Implants Transaction | |
| 27. Beginning in September 2012, the Spine Sales VP solicited the Brazilian Distributor to | |
| purchase approximately $1.5 million of Orthofix implants that had not yet been approved | |
| by ANVISA. Thus – as with the summer 2012 sales transaction with the Brazilian | |
| Distributor – this product could not be shipped into Brazil until that approval occurred. | |
| 28. The Brazilian Distributor indicated that it would agree to the purchase but only under the | |
| following two conditions: (i) the ability to renegotiate the payment terms if ANVISA | |
| approval did not occur by the end of 2012 (just three months away) and (ii) one year to | |
| pay for the product. | |
| 29. The Spine Sales VP forwarded an email to Hammel concerning the transaction terms for | |
| his approval. Hammel approved the transaction and recognized the revenue from this | |
| 7 | |
| transaction immediately upon shipping the implants to the Brazilian Distributor’s | |
| warehouse located in the United States. | |
| 30. This revenue recognition was improper because the Brazilian Distributor’s obligation to | |
| pay, and the payment terms themselves, were contingent upon ANVISA approval and, | |
| therefore, revenue recognition was inconsistent with Orthofix’s accounting policy | |
| because it did not meet the fixed or determinable criteria or the collectability criteria. | |
| d. Hammel Did Not Reassess Revenue Recognition After Meeting with Brazilian | |
| Distributor | |
| 31. In December 2012, Hammel learned from an email sent to him by the Spine Sales VP | |
| that the Brazilian Distributor’s President had in June 2012 informed the then-Spine | |
| President and Spine Sales VP that it would not pay $4 million of its amounts payable by | |
| the end of December 2012. Rather, the Brazilian Distributor’s President informed the | |
| then Spine President and Spine Sales VP that it would only pay $1.6 million of its | |
| amounts payable by December 2012 and the remainder by February 2013. | |
| 32. On December 1, 2012, Hammel forwarded the email to the New Spine President (who | |
| had previously served as the company’s Corporate CFO) and wrote: | |
| [The Brazilian Distributor’s President] says below they made a payment agreement | |
| with [the Spine President] . . . I have no idea what may have been promised. I do | |
| know that I fought pricing and terms concessions, but those were ultimately given at | |
| some point despite my denials. This was commonplace. I was told that I was the | |
| decision maker on pricing and terms and then secretly overridden. [The Spine Sales | |
| VP] did it all of the time – don’t know how much [the Spine President] was involved. | |
| 33. On December 7, 2012, the Brazilian Distributor’s President travelled to the U.S. to meet | |
| with Hammel and the Spine Sales VP. At that meeting, the Brazilian Distributor’s | |
| President provided a Power Point presentation with a detailed chronology of events on | |
| several sales transactions involving the Brazilian Distributor, including the implant- | |
| without-instruments transactions, the June and September 2012 transactions, and the | |
| payment plan related issues. | |
| 34. After this December 7 meeting, Hammel did not reassess the revenue that the company | |
| had previously recognized and disclosed in its financial statements with the Brazilian | |
| Distributor. Moreover, Hammel did not forward or provide the Power Point presentation | |
| to Orthofix’s then Corporate CFO. | |
| 35. As a result of this and other errors described previously and below, Orthofix materially | |
| misstated its financial results in its FY 2012 Form 10-K and corresponding earnings | |
| release. | |
| 8 | |
| D. Hammel Improperly Recognized Revenue with Italian and Spanish Distributors | |
| 36. In addition to the Brazilian Distributor, OSI had relationships with other international | |
| distributors including in Italy and Spain. | |
| 37. During his tenure as Spine’s CFO, Hammel became aware of extended payment terms | |
| being granted to OSI’s Italian and Spanish distributors as a result of those distributors | |
| experiencing financial difficulties. Hammel did not, however, evaluate the impact of | |
| these facts on Orthofix’s revenue recognition. | |
| 38. For example, in early December 2011, the Spine Sales VP emailed the Italian Distributor | |
| and solicited it to make a $400,000 order. The Italian Distributor’s President responded | |
| that it could make the order if they had extended payment terms of 180 days and the | |
| ability “in case of cash difficulties” to extend those payment terms. | |
| 39. Hammel was copied on these email exchanges and – despite the specifically identified | |
| financial difficulties in Italy – recognized the revenue associated with this order upon | |
| shipment. This revenue recognition was improper because payment terms were | |
| contingent upon timing of the Italian Distributor’s sell-through and payment receipt of | |
| the products and, therefore, revenue recognition was inconsistent with Orthofix’s | |
| accounting policy because it did not meet the fixed or determinable or collectability | |
| criteria. | |
| 40. Similarly, in early December 2011, the Spine Sales VP solicited the Spanish distributor to | |
| make a $300,000 order. The Spanish Distributor noted the difficult conditions in the | |
| Spanish economy at the time. The Spine Sales VP responded that “based on the expected | |
| challenges in Europe due to the instability of the financial institutions,” he could offer | |
| extended payment terms of 180 days for instruments and 150 days for implants. | |
| 41. In late December 2011, the Spine Sales VP forwarded the email exchange to Hammel for | |
| his approval of the extended payment terms. Hammel provided this approval and | |
| recognized the revenue from this transaction upon shipment of the products. This | |
| revenue recognition was improper because it did not meet the fixed or determinable or | |
| collectability criteria. | |
| E. Hammel Incorrectly Accounted for Certain Spinal Stimulation Product Transactions | |
| 42. Beginning in the first quarter of FY 2012, the Spine President began exploring | |
| opportunities to generate more revenue in the domestic spine market by selling spine | |
| stimulation products directly to wholesale distributors who would then resell them to | |
| doctors and hospitals. Prior to this time, Orthofix sold these products directly to doctors | |
| and hospitals. | |
| 43. At this time, the wholesale market for these products was dominated by an Orthofix | |
| competitor. To draw market share away from this competitor, the Spine President and | |
| Hammel determined to sell Orthofix spinal stimulation products at deeply discounted | |
| 9 | |
| prices-per-unit to the wholesalers, and pay a referral fee to the wholesaler that was | |
| termed a “commission.” | |
| 44. Hammel accounted for these commissions as expenses rather than as reductions to | |
| revenue. This accounting treatment was improper because where the vendor does not | |
| receive an identifiable benefit for the commissions, sales discounts such as these are | |
| presumed to be a reduction in the seller’s price pursuant to ASC 605-50-45-2. Thus, | |
| these commissions should have been treated as further price discounts and as a reduction | |
| in revenue. | |
| 45. Due to this improper accounting, Orthofix overstated its revenue by approximately $1.4 | |
| million in the third quarter of FY 2012, and a total of approximately $1.7 million in FY | |
| 2012. | |
| 46. Moreover, Hammel was aware of two spinal stimulation transactions in which the | |
| purchasers were granted rights to exchange the products for cervical stimulation products. | |
| 47. Because Orthofix could not and did not reasonably estimate the revenue recognition | |
| impact of the amount of future returns, Orthofix was precluded from recognizing revenue | |
| upon shipment in the above transactions pursuant to ASC 605-15-25-1(f). As a result, | |
| Orthofix overstated its revenue by over $650,000 in the third quarter of FY 2012. | |
| F. Hammel Made an Inaccurate Representation to Orthofix’s Independent Auditors | |
| 48. As of the company’s fiscal year 2012 audit – and as described by the conduct above – | |
| Hammel was aware that the company had entered into transactions with extended | |
| payment terms and that the company had made certain oral agreements such as the fact | |
| that the Brazilian Distributor’s payment for certain products was contingent on ANVISA | |
| approval. | |
| 49. Nevertheless, Hammel – in connection with an audit of the company’s FY 2012 financial | |
| statements – represented through a February 15, 2013 management representation letter4 | |
| provided directly to the independent auditors that: | |
| a. All significant oral agreements were made available to the auditors; | |
| b. There were no orders with extended credit terms; and | |
| c. All sales terms (express or implied), including all rights of returns were disclosed. | |
| 50. Hammel provided the misleading representation at the direction of a company officer or | |
| director, namely, the company’s then-Corporate CFO. | |
| 4 Hammel signed the management representation letter after he resigned from the company. | |
| 10 | |
| G. Orthofix’s Restatement | |
| 51. Orthofix materially misstated several of its annual and quarterly filings and | |
| corresponding earnings releases, failed to make and keep books and records which, in | |
| reasonable detail, accurately and fairly reflected the transactions and dispositions of the | |
| assets of the issuer, and failed to devise and maintain a system of internal accounting | |
| controls sufficient to provide reasonable assurance that transactions are recorded as | |
| necessary to permit the preparation of financial statements in conformity with generally | |
| accepted accounting principles. | |
| 52. Accordingly – in late March 2014 – Orthofix restated its financial statements for the first | |
| quarter of fiscal year 2013, all quarterly and annual periods in fiscal years 2012 and 2011, | |
| and the annual period for fiscal year 2010 as a result of misconduct. Orthofix also | |
| acknowledged certain material weaknesses in its internal controls over financial | |
| reporting. | |
| VIOLATIONS | |
| 53. Securities Act Section 17(a)(2) prohibits any person from obtaining money or property in | |
| the offer or sale of securities by means of any untrue statement of a material fact or any | |
| omission to state a material fact necessary in order to make the statements made, in light | |
| of the circumstances under which they were made, not misleading. | |
| 54. Securities Act Section 17(a)(3) prohibits any person from engaging in any transaction, | |
| practice, or course of business which operates or would operate as a fraud or deceit upon | |
| the purchaser in the offer or sale of securities. | |
| 55. Exchange Act Section 13(a) and Rules 13a-1, 13a-11, and 13a-13 thereunder require | |
| issuers to file such periodic and other reports as the Commission may prescribe and in | |
| conformity with such rules as the Commission may promulgate. Exchange Act Rules | |
| 13a-1, 13a-11, and 13a-13 require the filing of annual, current, and quarterly reports, | |
| respectively. Rule 12b-20 of the Exchange Act requires issuers to add such further | |
| material information, if any, as may be necessary to make the required statements, in the | |
| light of the circumstances under which they are made not misleading. | |
| 56. Exchange Act Section 13(b)(2)(A) requires issuers to “make and keep books, records, | |
| and accounts, which, in reasonable detail, accurately and fairly reflect the transactions | |
| and dispositions of the assets of the issuer.” Exchange Act Section 13(b)(2)(B) requires | |
| issuers to devise and maintain a system of internal accounting controls sufficient to | |
| provide reasonable assurances that transactions are recorded as necessary to permit the | |
| preparation of financial statements in conformity with generally accepted accounting | |
| principles. | |
| 57. Exchange Act Rule 13b2-1 prohibits any person from, directly or indirectly, falsifying or | |
| causing to be falsified, any book, record, or account subject to Exchange Act Section | |
| 13(b)(2)(A). | |
| 11 | |
| 58. Exchange Act Rule 13b2-2(b) prohibits any officer or director of an issuer or any other | |
| person acting under the direction thereof from directly or indirectly taking any action to | |
| mislead an accountant engaged in the performance of an audit if that person knew or | |
| should have known that such action, if successful, could result in rendering the issuer’s | |
| financial statements materially misleading. | |
| 59. As a result of the conduct described above, Hammel was a cause of Orthofix’s violations | |
| of Securities Act Sections 17(a)(2) and 17(a)(3) and Exchange Act Sections 13(a), | |
| 13(b)(2)(A), and 13(b)(2)(B) and Rules 12b-20, 13a-1, 13a-11, and 13a-13 thereunder. | |
| Hammel also willfully5 violated Exchange Act Rules 13b2-1 and 13b2-2(b). | |
| IV. | |
| In view of the foregoing, the Commission deems it appropriate to impose the sanctions | |
| agreed to in Respondent’s Offer. | |
| Accordingly, pursuant to Section 8A of the Securities Act, Sections 4C and 21C of the | |
| Exchange Act, and Rule 102(e)(1(iii) of the Commission’s Rules of Practice, it is hereby | |
| ORDERED, effectively immediately, that: | |
| A. Hammel shall cease and desist from committing or causing any violations and any future | |
| violations of Securities Act Section 17(a)(2) and 17(a)(3) and Exchange Act Sections | |
| 13(a), 13(b)(2)(A), 13(b)(2)(B), and Rules 12b-20, 13a-1, 13a-11, 13a-13, 13b2-1, and | |
| 13b2-2(b) thereunder. | |
| B. Hammel is denied the privilege of appearing or practicing before the Commission as an | |
| accountant. | |
| C. After two years from the date of this order, Respondent may request that the Commission | |
| consider his reinstatement by submitting an application (attention: Office of the Chief | |
| Accountant) to resume appearing or practicing before the Commission as: | |
| 1. a preparer or reviewer, or a person responsible for the preparation or | |
| review, of any public company’s financial statements that are filed with | |
| the Commission. Such an application must satisfy the Commission that | |
| Respondent’s work in his/her practice before the Commission will be | |
| reviewed either by the independent audit committee of the public company | |
| 5 A willful violation of the securities laws means merely “that the person charged with the duty knows what | |
| he is doing.” Wonsover v. SEC, 205 F.3d 408, 414 (D.C. Cir. 2000) (quoting Hughes v. SEC, 174 F.2d 969, 977 | |
| (D.C. Cir. 1949)). There is no requirement that the actor “also be aware that he is violating one of the Rules or | |
| Acts.” Id. (quoting Gearhart & Otis, Inc. v. SEC, 348 F.2d 798, 803 (D.C. Cir. 1965)). | |
| 12 | |
| for which he/she works or in some other acceptable manner, as long as | |
| he/she practices before the Commission in this capacity; and/or | |
| 2. an independent accountant. Such an application must satisfy the | |
| Commission that: | |
| (a) Respondent, or the public accounting firm with which he/she is | |
| associated, is registered with the Public Company Accounting | |
| Oversight Board (“Board”) in accordance with the Sarbanes-Oxley | |
| Act of 2002, and such registration continues to be effective; | |
| (b) Respondent, or the registered public accounting firm with which | |
| he/she is associated, has been inspected by the Board and that | |
| inspection did not identify any criticisms of or potential defects in | |
| the respondent’s or the firm’s quality control system that would | |
| indicate that the respondent will not receive appropriate | |
| supervision; | |
| (c) Respondent has resolved all disciplinary issues with the Board, and | |
| has complied with all terms and conditions of any sanctions | |
| imposed by the Board (other than reinstatement by the | |
| Commission); and | |
| (d) Respondent acknowledges his/her responsibility, as long as | |
| Respondent appears or practices before the Commission as an | |
| independent accountant, to comply with all requirements of the | |
| Commission and the Board, including, but not limited to, all | |
| requirements relating to registration, inspections, concurring | |
| partner reviews and quality control standards. | |
| D. The Commission will consider an application by Respondent to resume appearing or | |
| practicing before the Commission provided that his/her state CPA license is current and | |
| he/she has resolved all other disciplinary issues with the applicable state boards of | |
| accountancy. However, if state licensure is dependent on reinstatement by the | |
| Commission, the Commission will consider an application on its other merits. The | |
| Commission’s review may include consideration of, in addition to the matters referenced | |
| above, any other matters relating to Respondent’s character, integrity, professional | |
| conduct, or qualifications to appear or practice before the Commission. | |
| E. Within 30 days of the entry of this Order, Hammel shall pay a civil money penalty in the | |
| amount of $20,000 to the Securities and Exchange Commission. If timely payment is not | |
| made, additional interest shall accrue pursuant to 31 U.S.C. § 3717. Payment must be | |
| made in one of the following three ways: | |
| 13 | |
| (1) Respondent may transmit payment electronically to the Commission, which | |
| will provide detailed ACH transfer/Fedwire instructions upon request | |
| 6 | |
| ; | |
| (2) Respondent may make direct payment from a bank account via Pay.gov | |
| through the SEC website at http://www.sec.gov/about/offices/ofin.htm; or | |
| (3) Respondent may pay by certified check, bank cashier’s check, or United | |
| States postal money order, made payable to the Securities and Exchange | |
| Commission and hand-delivered or mailed to: | |
| Enterprise Services Center | |
| Accounts Receivable Branch | |
| HQ Bldg., Room 181, AMZ-341 | |
| 6500 South MacArthur Boulevard | |
| Oklahoma City, OK 73169 | |
| Payments by check or money order must be accompanied by a cover letter identifying | |
| Jeffrey Hammel as a Respondent in these proceedings, and the file number of these proceedings; | |
| a copy of the cover letter and check or money order must be sent to Antonia Chion, Division of | |
| Enforcement, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549- | |
| 5720. | |
| F. Pursuant to Section 308(a) of the Sarbanes-Oxley Act of 2002, as amended, a Fair Fund | |
| is created for the penalties referenced in paragraph IV.E above. This Fair Fund may be | |
| added to or combined with the fair fund established in In the Matter of Orthofix | |
| International, N.V., (AP File No. 3-17791; Release No. 10281, January 18, 2017) and/or | |
| may be added to or combined with fair funds established for the civil penalties paid by other | |
| Respondents for conduct arising in relation to the violative conduct at issue in this | |
| proceeding or the Orthofix proceeding, in order for the combined fair funds to be distributed | |
| to harmed investors affected by the same violative conduct. Amounts ordered to be paid as | |
| civil money penalties pursuant to this Order shall be treated as penalties paid to the | |
| government for all purposes, including all tax purposes. To preserve the deterrent effect | |
| of the civil penalty, Respondent agrees that in any Related Investor Action, it shall not | |
| argue that it is entitled to, nor shall it benefit by, offset or reduction of any award of | |
| compensatory damages by the amount of any part of Respondent’s payment of a civil | |
| penalty in this action (“Penalty Offset”). If the court in any Related Investor Action | |
| grants such a Penalty Offset, Respondent agrees that it shall, within 30 days after entry of | |
| a final order granting the Penalty Offset, notify the Commission’s counsel in this action | |
| and pay the amount of the Penalty Offset to the Securities and Exchange Commission. | |
| Such a payment shall not be deemed an additional civil penalty and shall not be deemed | |
| 6 | |
| The minimum threshold for transmission of payment electronically is $1,000,000. For amounts below the | |
| threshold, respondents must make payments pursuant to option (2) or (3) above. | |
| 14 | |
| to change the amount of the civil penalty imposed in this proceeding. For purposes of | |
| this paragraph, a “Related Investor Action” means a private damages action brought | |
| against Respondent by or on behalf of one or more investors based on substantially the | |
| same facts as alleged in the Order instituted by the Commission in this proceeding. | |
| G. It is further ordered that, solely for purposes of exceptions to discharge set forth in | |
| Section 523 of the Bankruptcy Code, 11 U.S.C. §523, the findings in this Order are true | |
| and admitted by Respondent, and further, any debt for disgorgement, prejudgment | |
| interest, civil penalty or other amounts due by Respondent under this Order or any other | |
| judgment, order, consent order, decree or settlement agreement entered in connection | |
| with this proceeding, is a debt for the violation by Respondent of the federal securities | |
| laws or any regulation or order issued under such laws, as set forth in Section 523(a)(19) | |
| of the Bankruptcy Code, 11 U.S.C. §523(a)(19). | |
| By the Commission. | |
| Brent J. Fields | |
| Secretary | |